<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02989454</url>
  </required_header>
  <id_info>
    <org_study_id>2/005/15</org_study_id>
    <nct_id>NCT02989454</nct_id>
  </id_info>
  <brief_title>Persistent Symptoms and Early Incomplete Recovery After Acute Stress-induced Cardiomyopathy: Is There Ongoing Heart Distress? The HEROIC Study</brief_title>
  <acronym>HEROIC</acronym>
  <official_title>Persistent Symptoms and Early Incomplete Recovery After Acute Stress-induced Cardiomyopathy: Is There Ongoing Heart Distress? The HEROIC Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aberdeen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Grampian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aberdeen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute stress induced (Tako-tsubo) cardiomyopathy (TTC) or broken heart syndrome, a condition
      typically occurring after acute stress has a death rate similar to heart attacks and is
      frequently associated with long-term symptoms (fatigue and exercise limitation). There are no
      effective therapies. The investigators have recently showed that there is a profound shortage
      of energy in the hearts of Tako Tsubo Cardiomyopathy patients in the days after acute
      presentation with only partial recovery by four months. The investigators would now like to
      establish whether this recovers after at least one year, or persists, and also to investigate
      the mechanisms responsible for exercise limitation after recovery from the acute phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tako Tsubo Cardiomyopathy presents with sudden onset of chest pain that mimics a myocardial
      infarction (MI) and is precipitated by major emotional/physical stress. Classically, the
      coronary arteries are normal and yet, the left ventricular (LV) angiogram shows a
      characteristic, extensive and severe wall motion abnormality, some develop cardiogenic shock,
      cardiac rupture or embolic stroke. In the weeks following onset, the wall motion
      abnormalities gradually recover: this led to the assumption that Tako Tsubo Cardiomyopathy is
      self-limiting, reinforced by the absence of myocardial damage on cardiac Magnetic Resonance
      Imaging. However, the investigators and others have shown that Tako Tsubo Cardiomyopathy
      recovery is not rapid, being characterised by severe global oedema, which persists for 3-4
      months after presentation. The investigators showed profound decrease in cardiac energetics
      during the acute Tako Tsubo Cardiomyopathy phase compared to healthy controls. This improved
      significantly at follow up but remained reduced compared to healthy controls.

      These objective findings of incompletely resolved myocardial oedema and energetic impairment
      are in contrast with the more rapid apparent recovery of Left Ventricular Ejection Fraction
      but are in keeping with the persistence of symptoms previously reported in literature and
      with the investigators' own clinical observations from the Tako Tsubo Cardiomyopathy
      follow-up clinic at the institution.

      The persistence of symptoms (fatigue, recurrent chest pains, decreased exercise capacity)
      could be due to either:

        1. Subclinical degree of impairment in cardiac energetics/function (reflecting either an
           even more prolonged status of incomplete recovery or a pre-existent cardiomyopathy)
           which despite a normalised for almost normalised ejection fraction at rest results in
           cardiac limitation during exercise, or

        2. Physical deconditioning after an acute, severe illness.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac energetics by cardiac magnetic resonance imaging</measure>
    <time_frame>One year or longer after diagnosis</time_frame>
    <description>Cardiac magnetic resonance imaging and spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>One year or longer after diagnosis</time_frame>
    <description>Cardiopulmonary exercise testing</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Tako-tsubo Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Tako Tsubo Cardiomyopathy patients</arm_group_label>
    <description>Any patient who has suffered from Tako Tsubo Cardiomyopathy since 2011.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assessment of exercise capacity and cardiac energetics</intervention_name>
    <description>Cardiopulmonary exercise testing and Magnetic Resonance Spectroscopy</description>
    <arm_group_label>Tako Tsubo Cardiomyopathy patients</arm_group_label>
    <other_name>MRI, MRS and CPEX</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples for genetic analysis will be stored.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient that has been diagnosed with Tako Tsubo Cardiomyopathy since 2011.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient diagnosed with Tako Tsubo Cardiomyopathy in Aberdeen, Glasgow and
             Inverness since 2011.

        Exclusion Criteria:

          -  Contraindication to magnetic resonance scanning such as an implantable cardiac device,
             etc for those undergoing magnetic resonance imaging only (they can attend for
             cardiopulmonary exercise testing and bloods).

          -  Inability to exercise on a treadmill (they can attend for magnetic resonance imaging
             and bloods).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dana Dawson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aberdeen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana Dawson, PhD</last_name>
    <phone>01224 437969</phone>
    <email>dana.dawson@abdn.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Scally, MD</last_name>
    <phone>01224 559573</phone>
    <email>carolinescally@abdn.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiac Research Office, Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Aberdeenshire</state>
        <zip>AB25 2ZD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Dawson, PhD</last_name>
      <phone>01224 437969</phone>
      <email>dana.dawson@abdn.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Amelia Rudd, HND</last_name>
      <phone>01224 559573</phone>
      <email>a.e.rudd@abdn.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008 Mar;155(3):408-17. doi: 10.1016/j.ahj.2007.11.008. Epub 2008 Jan 31. Review.</citation>
    <PMID>18294473</PMID>
  </reference>
  <reference>
    <citation>Sy F, Basraon J, Zheng H, Singh M, Richina J, Ambrose JA. Frequency of Takotsubo cardiomyopathy in postmenopausal women presenting with an acute coronary syndrome. Am J Cardiol. 2013 Aug 15;112(4):479-82. doi: 10.1016/j.amjcard.2013.04.010. Epub 2013 May 16.</citation>
    <PMID>23683950</PMID>
  </reference>
  <reference>
    <citation>Sharkey SW, Windenburg DC, Lesser JR, Maron MS, Hauser RG, Lesser JN, Haas TS, Hodges JS, Maron BJ. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol. 2010 Jan 26;55(4):333-41. doi: 10.1016/j.jacc.2009.08.057.</citation>
    <PMID>20117439</PMID>
  </reference>
  <reference>
    <citation>Elesber AA, Prasad A, Lennon RJ, Wright RS, Lerman A, Rihal CS. Four-year recurrence rate and prognosis of the apical ballooning syndrome. J Am Coll Cardiol. 2007 Jul 31;50(5):448-52. Epub 2007 Jul 16.</citation>
    <PMID>17662398</PMID>
  </reference>
  <reference>
    <citation>Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K, Aldrovandi A, Francone M, Desch S, Gutberlet M, Strohm O, Schuler G, Schulz-Menger J, Thiele H, Friedrich MG. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA. 2011 Jul 20;306(3):277-86. doi: 10.1001/jama.2011.992.</citation>
    <PMID>21771988</PMID>
  </reference>
  <reference>
    <citation>Neil C, Nguyen TH, Kucia A, Crouch B, Sverdlov A, Chirkov Y, Mahadavan G, Selvanayagam J, Dawson D, Beltrame J, Zeitz C, Unger S, Redpath T, Frenneaux M, Horowitz J. Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRI. Heart. 2012 Sep;98(17):1278-84. doi: 10.1136/heartjnl-2011-301481. Epub 2012 Jul 11.</citation>
    <PMID>22791656</PMID>
  </reference>
  <reference>
    <citation>Horowitz JD, Nguyen TH. Role of echocardiography in tako-tsubo cardiomyopathy: beyond diagnosis? JACC Cardiovasc Imaging. 2014 Feb;7(2):130-2. doi: 10.1016/j.jcmg.2013.09.021.</citation>
    <PMID>24524742</PMID>
  </reference>
  <reference>
    <citation>Singh K, Carson K, Usmani Z, Sawhney G, Shah R, Horowitz J. Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy. Int J Cardiol. 2014 Jul 1;174(3):696-701. doi: 10.1016/j.ijcard.2014.04.221. Epub 2014 Apr 26. Review.</citation>
    <PMID>24809923</PMID>
  </reference>
  <reference>
    <citation>Chen X, Lee G, Maher BS, Fanous AH, Chen J, Zhao Z, Guo A, van den Oord E, Sullivan PF, Shi J, Levinson DF, Gejman PV, Sanders A, Duan J, Owen MJ, Craddock NJ, O'Donovan MC, Blackman J, Lewis D, Kirov GK, Qin W, Schwab S, Wildenauer D, Chowdari K, Nimgaonkar V, Straub RE, Weinberger DR, O'Neill FA, Walsh D, Bronstein M, Darvasi A, Lencz T, Malhotra AK, Rujescu D, Giegling I, Werge T, Hansen T, Ingason A, Nöethen MM, Rietschel M, Cichon S, Djurovic S, Andreassen OA, Cantor RM, Ophoff R, Corvin A, Morris DW, Gill M, Pato CN, Pato MT, Macedo A, Gurling HM, McQuillin A, Pimm J, Hultman C, Lichtenstein P, Sklar P, Purcell SM, Scolnick E, St Clair D, Blackwood DH, Kendler KS; GROUP investigators; International Schizophrenia Consortium. GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. Mol Psychiatry. 2011 Nov;16(11):1117-29. doi: 10.1038/mp.2010.96. Epub 2010 Sep 14.</citation>
    <PMID>20838396</PMID>
  </reference>
  <reference>
    <citation>Ashbrook DG, Williams RW, Lu L, Hager R. A cross-species genetic analysis identifies candidate genes for mouse anxiety and human bipolar disorder. Front Behav Neurosci. 2015 Jul 1;9:171. doi: 10.3389/fnbeh.2015.00171. eCollection 2015.</citation>
    <PMID>26190982</PMID>
  </reference>
  <reference>
    <citation>McCalmon SA, Desjardins DM, Ahmad S, Davidoff KS, Snyder CM, Sato K, Ohashi K, Kielbasa OM, Mathew M, Ewen EP, Walsh K, Gavras H, Naya FJ. Modulation of angiotensin II-mediated cardiac remodeling by the MEF2A target gene Xirp2. Circ Res. 2010 Mar 19;106(5):952-60. doi: 10.1161/CIRCRESAHA.109.209007. Epub 2010 Jan 21.</citation>
    <PMID>20093629</PMID>
  </reference>
  <reference>
    <citation>Pison L, De Vusser P, Mullens W. Apical ballooning in relatives. Heart. 2004 Dec;90(12):e67.</citation>
    <PMID>15547001</PMID>
  </reference>
  <reference>
    <citation>Kumar G, Holmes DR Jr, Prasad A. &quot;Familial&quot; apical ballooning syndrome (Takotsubo cardiomyopathy). Int J Cardiol. 2010 Oct 29;144(3):444-5. doi: 10.1016/j.ijcard.2009.03.078. Epub 2009 Apr 17.</citation>
    <PMID>19375184</PMID>
  </reference>
  <reference>
    <citation>Sharkey SW, Lips DL, Pink VR, Maron BJ. Daughter-mother tako-tsubo cardiomyopathy. Am J Cardiol. 2013 Jul 1;112(1):137-8. doi: 10.1016/j.amjcard.2013.02.063. Epub 2013 Apr 2.</citation>
    <PMID>23561588</PMID>
  </reference>
  <reference>
    <citation>Caretta G, Robba D, Vizzardi E, Bonadei I, Raddino R, Metra M. Tako-tsubo cardiomyopathy in two sisters: a chance finding or familial predisposition? Clin Res Cardiol. 2015 Jul;104(7):614-6. doi: 10.1007/s00392-015-0837-0. Epub 2015 Mar 6.</citation>
    <PMID>25743177</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>December 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2016</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Takotsubo Cardiomyopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

